Climb Bio (CLYM) Stock Price, Quote, News & History

Comments

Climb Bio Inc (CLYM) Stock Price, Quote, News & History

CLYMNASDAQ

Trade with Public

$9.16

0.343.85%

At close: Apr 17, 5:00 PM EST

$9.38

0.222.40%

After Hours: 6:51 PM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$8.97

Close

$9.16

Volume / Avg.

450.92K / 574.92K

Day Range

$8.59 - $9.40

52 Wk Range

1.13 - 9.25

Market Cap

$447.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

75

Short Interest

10.93%

Days to Cover

4

Recent Climb Bio Inc News

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-54.36M

Investing Cash Flow (TTM)

2.83M

Financing Cash Flow (TTM)

-21.00K

Free Cash Flow (TTM)

-54.54M

Capital Expenditure (TTM)

-186.00K

Net Change in Cash (TTM)

-51.54M

Analyst Trends and Forecast

2

Dec 25

1

Feb

7

Mar

2

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$335.58M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

2.62

Earnings Yield % (TTM)

-10.00%

Earnings Yield % (FWD)

-11.42%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.36

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$35.69M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$8.97

Close

$9.16

Volume / Avg.

450.92K / 574.92K

Day Range

$8.59 - $9.40

52 Wk Range

1.13 - 9.25

Market Cap

$447.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

75

Short Interest

10.93%

Days to Cover

4

About

Sector

Health Care

Industry

Biotechnology

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases suc...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Climb Bio (CLYM) stock?

A

You can purchase shares of Climb Bio (NASDAQ:CLYM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Climb Bio (CLYM) competitors?

A

Other companies in Climb Bio’s space includes: Cabaletta Bio Inc (NASDAQ:CABA), Monopar Therapeutics Inc (NASDAQ:MNPR), Altimmune Inc (NASDAQ:ALT), Armata Pharmaceuticals Inc (AMEX:ARMP) and Palisade Bio Inc (NASDAQ:PALI).

Q

What is the forecast, or price target, for Climb Bio (CLYM) stock?

A

Climb Bio has a consensus price target of $16.09.

Q

What is the current price for Climb Bio (CLYM)?

A

The stock price for Climb Bio (NASDAQ: CLYM) is $9.38 last updated April 17, 2026 at 6:51 PM EDT.

Q

Does Climb Bio (CLYM) pay a dividend?

A

There are no upcoming dividends for Climb Bio.

Q

When is Climb Bio (NASDAQ:CLYM) reporting earnings?

A

Climb Bio does not have any upcoming earnings scheduled.

Q

Is Climb Bio (CLYM) going to split?

A

There is no upcoming split for Climb Bio.

Q

What sector and industry does Climb Bio (CLYM) operate in?

A

Climb Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Monopar Therapeutics Inc

ARMP

Eupraxia Pharmaceuticals Inc

Key Statistics

Open

$8.97

Close

$9.16

Volume / Avg.

450.92K / 574.92K

Day Range

$8.59 - $9.40

52 Wk Range

1.13 - 9.25

Market Cap

$447.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

75

Short Interest

10.93%

Days to Cover

4

Recent Climb Bio Inc News

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-54.36M

Investing Cash Flow (TTM)

2.83M

Financing Cash Flow (TTM)

-21.00K

Free Cash Flow (TTM)

-54.54M

Capital Expenditure (TTM)

-186.00K

Net Change in Cash (TTM)

-51.54M

Analyst Trends and Forecast

2

Dec 25

1

Feb

7

Mar

2

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$335.58M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

2.62

Earnings Yield % (TTM)

-10.00%

Earnings Yield % (FWD)

-11.42%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.36

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$35.69M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$8.97

Close

$9.16

Volume / Avg.

450.92K / 574.92K

Day Range

$8.59 - $9.40

52 Wk Range

1.13 - 9.25

Market Cap

$447.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

75

Short Interest

10.93%

Days to Cover

4

About

Sector

Health Care

Industry

Biotechnology

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases suc...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry